Clinical Trials List
Protocol NumberJ2A-MC-GZPW
NCT Number(ClinicalTrials.gov Identfier)NCT07241390
Active
2026-01-01 - 2031-09-18
Phase III
Not yet recruiting1
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Orforglipron on the Incidence of Major Adverse Cardiovascular Events in Participants with Established Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
-
Trial Applicant
ELI LILLY AND COMPANY(TAIWAN), INC.
-
Sponsor
ELI LILLY AND COMPANY(TAIWAN), INC.
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/09/11
Investigators and Locations
Co-Principal Investigator
- 黃天祈 無
- Cheng-An Chiu 無
- Ye-Hsu Lu 無
- 吳韋璁 無
- Chun-Yuan Chu 無
Co-Principal Investigator
- Ping-Yen Liu 無
- 張尹凡 無
- Wei-Hung Lin 無
- 張秦松 無
- 李文煌 無
- 張獻元 無
- 吳至行 無
Co-Principal Investigator
- 洪元 無
- 陳志維 無
- 蕭卜源 無
- 陳彥舟 無
- Yung-Ta Kao 無
- Chien-Yi Hsu 無
- 鄭宇倫 無
Co-Principal Investigator
- 蘇乾嘉 無
- MAO-HSIN LIN 無
- JEN-KUANG LEE 無
- 柯宗佑 無
- Chih-Fan Yeh 無
- 陳盈憲 無
- CHO-KAI WU 無
- 黃慶昌 無
- YEN-HUNG LIN 無
- 孟士瑋 無
- Tzung-Dau Wang 無
- 林柏志 無
Co-Principal Investigator
- I-Ming Chen 無
- 郭姿廷 無
- 張俊欽 無
- Chern-En Chiang 無
- 黃偉銘 無
- Tse-Min Lu 無
- Wen-Chung Yu 無
- 陳泰位 無
- 張皓智 無
- Kang-Ling Wang 無
- 吳承學 無
- 游偉光 無
Principal Investigator
Pao-Hsien Chu
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Condition/Disease
Atherosclerosis Cardiovascular Disease Chronic Kidney Disease
Objectives
The purpose of this study is to measure cardiovascular outcomes with orforglipron compared with placebo in participants with atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). Participation in the study will last about 5 years.
Test Drug
Orforglipron (LY3502970)
Placebo
Placebo
Active Ingredient
Orforglipron (LY3502970)
Placebo
Placebo
Dosage Form
Tablet
Tablet
Tablet
Dosage
MG
MG
MG
Endpoints
Time to First Occurrence of Composite Endpoint of Major Cardiovascular Events Composite endpoint includes nonfatal myocardial infarction, nonfatal stroke, hospitalization or urgent visit due to heart failure, coronary revascularization, or all-cause death Baseline up to end of study (about 5 years)
Inclution Criteria
Have established ASCVD and/or CKD
Exclusion Criteria
Have type 1 diabetes
Have had a major heart condition within 60 days prior to screening
Have New York Heart Association Functional Classification Class IV heart failure
Have had a major heart condition within 60 days prior to screening
Have New York Heart Association Functional Classification Class IV heart failure
The Estimated Number of Participants
-
Taiwan
166 participants
-
Global
7140 participants
